Immune Response to the COVID-19 Vaccine
Explore the effects on immune response to include a potential third vaccine for the cancer cohort.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated May 20, 2022 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Early Phase 1
- Sponsor
- University of Arizona
- Interventions being studied
- Biological: SARS-COV2 Pfizer Vaccine
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Patients must have active solid tumor malignancy diagnosis 2. On active chemotherapy 3. Received two prior SARS-COV2 Pfizer vaccines 4. Age ≥ 18 years 5. Ability to understand and the willingness to sign a written informed consent 6. Agree to comply with study procedures 7. Subjects previously enrolled under the main study
1. History of HIV or organ/bone marrow transplant 2. Actively receiving immunotherapy 3. On active, chronic immunosuppression (\>10 mg daily dose of prednisone equivalent) 4. Currently incarcerated or residence of another state 5. Speaks a language other than English.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of ArizonaTucson, Arizona
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 20, 2022. Always confirm current availability with the study team.